Ondansetron Baxter (Ondansetron)

Ondansetron Baxter is a selective 5‑HT3 receptor antagonist used in the prevention and treatment of nausea and vomiting across several clinical pathways.

• Chemotherapy‑induced nausea and vomiting: helps control acute and delayed episodes in cancer patients receiving cytotoxic therapy.
• Radiotherapy‑induced nausea and vomiting: reduces vomiting associated with abdominal or pelvic radiation.
• Post‑operative nausea and vomiting: decreases the incidence of nausea after general anaesthesia.
• Pregnancy‑related hyperemesis gravidarum (when other therapies are ineffective): provides symptomatic relief under specialist supervision.

• Ondansetron blocks the serotonin 5‑HT3 receptors located on vagal afferent nerves in the gastrointestinal tract and in the chemoreceptor trigger zone of the brain. By preventing serotonin from binding to these receptors, it interrupts the neural signaling cascade that initiates the vomiting reflex, thereby reducing nausea and vomiting.

Adverse reactions to ondansetron are generally dose‑related and may vary with the route of administration.

Common Side Effects

• Headache: mild to moderate intensity.
• Constipation: reduced bowel movements.
• Diarrhoea: loose stools.
• Fatigue: feeling of tiredness.
• Dizziness: transient light‑headedness.

Serious or Rare Side Effects

• Cardiac arrhythmia: QT‑interval prolongation, especially with intravenous use.
• Severe hypersensitivity: rash, itching, swelling or anaphylaxis.
• Serotonin syndrome: agitation, hyperreflexia, fever when combined with other serotonergic agents.
• Hepatic enzyme elevation: increased ALT/AST levels.
• Vision changes: blurred vision or transient visual disturbances.

When prescribing ondansetron, clinicians should consider patient‑specific factors and follow standard safety practices.

• Cardiac assessment: obtain baseline ECG in patients with known cardiac disease or electrolyte imbalance.
• Electrolyte monitoring: correct hypokalaemia or hypomagnesaemia before use.
• Drug‑interaction review: avoid concurrent use with other QT‑prolonging agents.
• Pregnancy and lactation: weigh benefits against potential risks; use only if clearly indicated.
• Renal/hepatic impairment: dose adjustment may be required in severe dysfunction.
• Store at below 25°C: keep in the original container, protect from moisture and light.

Ondansetron can modify the pharmacokinetics or cardiac safety profile of several medicines.

Major Interactions (Avoid)

• Aprepitant + ondansetron: additive QT prolongation risk.
• Certain anti‑malarial drugs (e.g., quinine): may increase QT interval.
• Tramadol: heightened risk of serotonin syndrome.

Moderate Interactions (Monitor Closely)

• Antidepressants (SSRIs, SNRIs): monitor for serotonin syndrome.
• Antifungal azoles (ketoconazole, fluconazole): may raise ondansetron plasma levels.
• Macrolide antibiotics (erythromycin, clarithromycin): modest QT prolongation potential.